Douglas Pagán, chief financial officer, Paratek Pharmaceuticals, Inc., has resigned, effective April 5, 2019, to join an early-stage biopharmaceutical company. Mr. Pagán has entered into a consulting agreement with Paratek through December 23, 2019 to assist the company in the transition of his responsibilities. Paratek has initiated a search to identify and recruit a new candidate for the role of chief financial officer.
 
Sarah Higgins, Paratek’s vice president and controller, will serve as the company’s principal financial officer and principal accounting officer as the company conducts a search for a new chief financial officer.
 
“I want to thank Doug for his many valued contributions to the company,” said Michael Bigham, chief executive officer and chairman of the board of Paratek. “Doug has played an important role in helping us transform Paratek from a development stage company to a commercial company while maintaining a strong balance sheet to support the commercialization of NUZYRA, the first once daily oral and IV antibiotic approved to treat both CABP and ABSSSI in nearly 20 years.  We wish him continued success as he returns to his passion of working with an early stage therapeutics company.”